Withdrawal of Alpha Blocker Therapy Following Initial Combination Therapy with 5 Alpha-Reductase Inhibitor (5ARI) Dutasteride for Benign Prostatic Hyperplasia: A Randomised Controlled Trial on Efficacy

被引：0
|
作者：
Ho, C. C. K. Ho [1 ]
Krishna, K. [1 ]
Zulkifli, M. Z. [1 ]
机构：
[1] Univ Kebangsaan Malaysia, Med Ctr, Kuala Lumpur, Malaysia
来源：
BJU INTERNATIONAL | 2013年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
P95
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [31] The Economic Impact of Delaying 5-Alpha Reductase Inhibitor Therapy in Men Receiving Treatment for Symptomatic Benign Prostatic Hyperplasia
    Naslund, Michael
    Eaddy, Michael T.
    Hogue, Susan L.
    Kruep, Eric J.
    Shah, Manan B.
    AMERICAN HEALTH AND DRUG BENEFITS, 2011, 4 (03): : 155 - 161
  • [32] FINASTERIDE, AN INHIBITOR OF 5-ALPHA-REDUCTASE, SUPPRESSES PROSTATIC DIHYDROTESTOSTERONE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
    MCCONNELL, JD
    WILSON, JD
    GEORGE, FW
    GELLER, J
    PAPPAS, F
    STONER, E
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (03): : 505 - 508
  • [33] Long-term therapy with the dual 5α-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia
    Schulman, C
    Pommerville, P
    Höfner, K
    Wachs, B
    BJU INTERNATIONAL, 2006, 97 (01) : 73 - 79
  • [34] SYSTEMATIC REVIEW COMPARING THE EFFICACY OF THE 5-ALPHA REDUCTASE INHIBITORS (5-ARIS) DUTASTERIDE AND FINASTERIDE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)
    Conte, T.
    Truzzi, J. C.
    Tannus, G.
    Fonseca, M.
    VALUE IN HEALTH, 2012, 15 (04) : A192 - A192
  • [35] THE α-BLOCKER-ONLY-TREATMENT AND THE α-BLOCKER AND 5-ALPHA-REDUCTASE INHIBITOR COMBINATION TREATMENT IN BENIGN PROSTATIC HYPERPLASIA; 10 YEARS LONG-TERM RESULT
    Chang, Hyuk Soo
    Kim, Byung Hoon
    Shin, Teak Jun
    Kim, Chun Il
    Park, Choal Hee
    Park, Jae Shin
    Kim, Duk Yoon
    Jung, Hee Chang
    Lee, Kyung Seop
    JOURNAL OF UROLOGY, 2011, 185 (04): : E787 - E787
  • [36] CELLULAR MECHANISMS OF 5-ALPHA REDUCTASE INHIBITOR TREATMENT RESISTANCE IN BENIGN PROSTATIC HYPERPLASIA
    Joseph, Diya Binoy
    Henry, Gervaise
    Malewska, Alicia
    Reese, Jeffrey
    Mauck, Ryan
    Gahan, Jeffrey
    Hutchinson, Ryan
    Mohler, James
    Roehrborn, Claus
    Strand, Douglas
    JOURNAL OF UROLOGY, 2021, 206 : E201 - E201
  • [37] Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
    Kim, Won
    Jung, Jae Hung
    Kang, Tae Wook
    Song, Jae Mann
    Chung, Hyun Chul
    KOREAN JOURNAL OF UROLOGY, 2014, 55 (01) : 52 - 56
  • [38] Evaluation of Sex Hormone Levels in Benign Prostatic Hyperplasia Patients Treated with 5 Alpha-Reductase Inhibitor (Finasteride) in Amara city/Iraq
    Hashim, Nidhal A.
    Khalifa, Ahmed A.
    Mohammed, Mukhtar K.
    BAGHDAD SCIENCE JOURNAL, 2020, 17 (01) : 1 - 8
  • [39] 5-ALPHA REDUCTASE INHIBITORS SUPPRESS DIHYDROTESTOSTERONE IN BENIGN PROSTATE HYPERPLASIA REQUIRING SURGERY, AND CAUSE STEROIDOGENESIS VIA 5ARI INDUCED PATHWAY
    Forbes, Connor
    Miller, Nicole L.
    Case, Thomas
    Strand, Douglas
    Liu, Qi
    Ramirez-Solano, Marisol
    Cates, Justin M.
    Porter, Ned A.
    Kim, Hye-Young H.
    Wages, Phillip
    Mohler, James L.
    Matusik, Robert J.
    Jin, Ren Jie
    JOURNAL OF UROLOGY, 2022, 207 (05): : E272 - E272
  • [40] Efficacy and tolerability of the dual 5α-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men
    Roehrborn, C. G.
    Ray, P.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (04) : 432 - 438
12345